1. LBA-007Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable mCRC. (2nd July 2019) Authors: Cremolini, C; Antoniotti, C; Lonardi, S; Rossini, D; Morano, F; Cordio, S; Bergamo, F; Marmorino, F; Maiello, E; Passardi, A; Masi, G; Tamburini, E; Santini, D; Grande, R; Zaniboni, A; Granetto, C; Murgioni, S; Aprile, G; Delliponti, L; Boni, L Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. (11th June 2018) Authors: Malorni, L; Curigliano, G; Minisini, A M; Cinieri, S; Tondini, C A; D'Hollander, K; Arpino, G; Bernardo, A; Martignetti, A; Criscitiello, C; Puglisi, F; Pestrin, M; Sanna, G; Moretti, E; Risi, E; Biagioni, C; McCartney, A; Boni, L; Buyse, M; Migliaccio, I Journal: Annals of oncology Issue: Volume 29:Number 8(2018) Page Start: 1748 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 1904PMolecular signature in malignant pleural mesothelioma (MPM): Preliminary data of Italian RAMES study. (23rd October 2018) Authors: Zanelli, F; Pagano, M; Bonelli, C; Gnoni, R; Boni, L; Ceresoli, G L; Larocca, M; Tiseo, M; Zucali, P; Grosso, F; Cappuzzo, F; Ciarrocchi, A; Torricelli, F; Pinto, C Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. O-017FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in mCRC: Final results of the phase II randomized MOMA trial by GONO. (20th June 2018) Authors: Marmorino, F; Cremolini, C; Bergamo, F; Pella, N; Antoniotti, C; Rossini, D; Dell'Aquila, E; Masi, G; Salvatore, L; Loupakis, F; Marcucci, L; Gemma, D; Cardellino, G; Borelli, B; Ricci, V; Delfanti, S; Mori, E; Tonini, G; Lonardi, S; Fontanini, G Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. O-017FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in mCRC: Final results of the phase II randomized MOMA trial by GONO. (20th June 2018) Authors: Marmorino, F; Cremolini, C; Bergamo, F; Pella, N; Antoniotti, C; Rossini, D; Dell'Aquila, E; Masi, G; Salvatore, L; Loupakis, F; Marcucci, L; Gemma, D; Cardellino, G; Borelli, B; Ricci, V; Delfanti, S; Mori, E; Tonini, G; Lonardi, S; Fontanini, G Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. LBA20TRIBE2: A phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable metastatic colorectal cancer (mCRC) patients (pts). (23rd October 2018) Authors: Cremolini, C; Antoniotti, C; Lonardi, S; Rossini, D; Pietrantonio, F; Cordio, S S; Murgioni, S; Marmorino, F; Maiello, E; Passardi, A; Masi, G; Tamburini, E; Santini, D; Grande, R; Zaniboni, A; Granetto, C; Loupakis, F; Delliponti, L; Boni, L; Falcone, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 1818TiPMulticentre, double-blind, randomised phase II study evaluating gemcitabine with or without ramucirumab as II line treatment for MPM. (23rd October 2018) Authors: Pagano, M; Zanelli, F; Gnoni, R; Bonelli, C; Tiseo, M; Boni, L; Ceresoli, G L; Zucali, P A; Grosso, F; Pasello, G; Cappuzzo, F; Pinto, C Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. (1st October 2019) Authors: Marmorino, F; Rossini, D; Lonardi, S; Moretto, R; Zucchelli, G; Aprile, G; Dell'Aquila, E; Ratti, M; Bergamo, F; Masi, G; Urbano, F; Ronzoni, M; Libertini, M; Borelli, B; Randon, G; Buonadonna, A; Allegrini, G; Pella, N; Ricci, V; Boccaccino, A Journal: Annals of oncology Issue: Volume 30:Number 12(2019) Page Start: 1969 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. OC-003 Short-term results of 2032 single port colorectal procedures with preoperative risk profiling: ecspect prospective multicentre registry. (22nd June 2015) Authors: Weiss, H; Gash, K; Dixon, A; Hell, T; Zorron, R; Vestweber, K-H; Vestweber, B; Boni, L; Brunner, W Journal: Gut Issue: Volume 64(2015)Supplement 1 Page Start: A2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Caution advised regarding lung recruitment before surfactant – Authors' reply. Issue 2 (February 2021) Authors: Vento, Giovanni; Ventura, M L; Pastorino, R; van Kaam, A H; Carnielli, V; Cools, F; Dani, C; Mosca, F; Polglase, G; Tagliabue, P; Boni, L; Cota, F; Tana, M; Tirone, C; Aurilia, C; Lio, A; Cost, S; D'Andrea, V; Lucente, M; Nigro, G Journal: Lancet Issue: Volume 9:Issue 2(2021) Page Start: e12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗